Page 229 - Read Online

Jagpal et al. Vessel Plus 2018;2:24 I http://dx.doi.org/10.20517/2574-1209.2018.27 Page 13 of 14

10. Friend PJ. Rejection reactions to different organ transplants. Eye 1995;9:190.
11. Azuma H, Tilney NL. Chronic graft rejection. Curr Opin Immunol 1994;6:770-6.
12. Lund LH, Khush KK, Cherikh WS, Goldfarb S, Kucheryavaya AY, Levvey BJ, Meiser B, Rossano JW, Chambers DC, Yusen RD,
Stehlik J; International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung
Transplantation: thirty-fourthadult heart transplantation report-2017; focus theme: allograft ischemic time. J Heart Lung Transplant
2017;36:1037-46.
13. Lindenfeld J, Miller GG, Shakar SF, Zolty R, Lowes BD, Wolfel EE, Mestroni L, Page RL 2nd, Kobashigawa J. Drug therapy in the
heart transplant recipient: part II: immunosuppressive drugs. Circulation 2004;110:3858-65.
14. Steiner RW, Awdishu L. Steroids in kidney transplant patients. Semin Immunopathol 2011;33:157-67.
15. Elion GB. The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine. Ann N Y Acad Sci 1993;685:400-7.
16. Wiseman AC. Immunosuppressive medications. Clin J Am Soc Nephrol 2016;11:332-43.
17. Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, Fedson S, Fisher P, Gonzales-Stawinski G, Martinelli L,
McGiffin D, Smith J, Taylor D, Meiser B, Webber S, Baran D, Carboni M, Dengler T, Feldman D, Frigerio M, Kfoury A, Kim D,
Kobashigawa J, Shullo M, Stehlik J, Teuteberg J, Uber P, Zuckermann A, Hunt S, Burch M, Bhat G, Canter C, Chinnock R, Crespo-
Leiro M, Delgado R, Dobbels F, Grady K, Kao W, Lamour J, Parry G, Patel J, Pini D, Towbin J, Wolfel G, Delgado D, Eisen H,
Goldberg L, Hosenpud J, Johnson M, Keogh A, Lewis C, O’Connell J, Rogers J, Ross H, Russell S, Vanhaecke J; International Society
of Heart and Lung Transplantation Guidelines. The International Society of Heart and Lung Transplantation Guidelines for the care of
heart transplant recipients. J Heart Lung Transplant 2010;29:914-56.
18. Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, Costanzo M, Eisen H, Dureau G, Ratkovec R, Hummel M,
Ipe D, Johnson J, Keogh A, Mamelok R, Mancini D, Smart F, Valantine H. A randomized active-controlled trial of mycophenolate
mofetil in heart transplant recipients. Mycophenolate mofetil investigators. Transplantation 1998;66:507-15.
19. Snell GI, Levvey BJ, Chin W, Kotsimbos T, Whitford H, Waters KN, Richardson M, Williams TJ. Sirolimus allows renal recovery in
lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2002;21:540-6.
20. Colombo D, Ammirati E. Cyclosporine in transplantation - a history of converging timelines. J Biol Regul Homeost Agents
2011;25:493-504.
21. Eisen HJ, Hobbs RE, Davis SF, Carrier M, Mancini DM, Smith A, Valantine H, Ventura H, Mehra M, Vachiery JL, Rayburn BK, Canver
CC, Laufer G, Costanzo MR, Copeland J, Dureau G, Frazier OH, Dorent R, Hauptman PJ, Kells C, Masters R, Michaud JL, Paradis I,
Renlund DG, Vanhaecke J, Mellein B, Mueller EA. Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant
recipients: a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine--results at 24 months
after transplantation. Transplantation 2001;71:70-8.
22. Watson CJ, Dark JH. Organ transplantation: historical perspective and current practice. Br J Anaesth 2012;108 Suppl 1:i29-42.
23. Fung JJ. Tacrolimus and transplantation: a decade in review. Transplantation 2004;77:S41-3.
24. Meiser BM, Groetzner J, Kaczmarek I, Landwehr P, Müller M, Jung S, Uberfuhr P, Fraunberger P, Stempfle HU, Weis M, Reichart
B. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? Transplantation
2004;78:591-8.
25. Armitage JM, Kormos RL, Griffith BP, Hardesty RL, Fricker FJ, Stuart RS, Marrone GC, Todo S, Fung J, Starzl TE. A clinical trial of
FK 506 as primary and rescue immunosuppression in cardiac transplantation. Transplant Proc 1991;23:1149-52.
26. Mukherjee S, Mukherjee U. A comprehensive review of immunosuppression used for liver transplantation. J Transplant
2009;2009:701464.
27. WHO. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. WHO: Geneva, Switzerland 2006.
28. Excellence NIfHaC. Type 2 diabetes: prevention in people at high risk. NICE guideline (PH38), 2012.
29. Sharif A, Cohney S. Post-transplantation diabetes-state of the art. Lancet Diabetes Endocrinol 2016;4:337-49.
30. Pham PT, Pham PM, Pham SV, Pham PA, Pham PC. New onset diabetes after transplantation (NODAT): an overview. Diabetes Metab
Syndr Obes 2011;4:175-86.
31. Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernández D, Kasiske BL, Kiberd B, Krentz A, Legendre C, Marchetti P, Markell
M, van der Woude FJ, Wheeler DC; International Expert Panel. New-onset diabetes after transplantation: 2003 international consensus
guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003;75:SS3-24.
32. Velleca A, Kittleson M, Patel J, Rafiei M, Osborne A, Ngan A, Hage A, Chang DH, Czer L, Kobashigawa J. Tacrolimus-versus
cyclosporine-induced diabetes leads to more diabetic complications after heart transplantation. J Heart Lung Transplant 2013;32:S202.
33. Reichart B, Meiser B, Viganò M, Rinaldi M, Yacoub M, Banner NR, Gandjbakhch I, Dorent R, Hetzer R, Hummel M. European
multicenter tacrolimus heart pilot study: three year follow-up. J Heart Lung Transplant 2001;20:249-50.
34. Taylor DO, Barr ML, Radovancevic B, Renlund DG, Mentzer RM Jr, Smart FW, Tolman DE, Frazier OH, Young JB, VanVeldhuisen
P. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressiveregimens in cardiac transplantation:
decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999;18:336-45.
35. Kobashigawa JA, Miller LW, Russell SD, Ewald GA, Zucker MJ, Goldberg LR, Eisen HJ, Salm K, Tolzman D, Gao J, Fitzsimmons
W, First R; the Study Investigators. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac
transplant patients: 1-year report. Am J Transplant 2006;6:1377-86.
36. Guethoff S, Meiser BM, Groetzner J, Eifert S, Grinninger C, Ueberfuhr P, Reichart B, Hagl C, Kaczmarek I. Ten-year results of a
randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation.
Transplantation 2013;95:629-34.